RT Journal Article SR Electronic T1 Bivalent booster effectiveness against severe COVID-19 outcomes in Finland, September 2022 – March 2023 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.03.02.23286561 DO 10.1101/2023.03.02.23286561 A1 Poukka, Eero A1 Nohynek, Hanna A1 Goebeler, Sirkka A1 Leino, Tuija A1 Baum, Ulrike YR 2023 UL http://medrxiv.org/content/early/2023/05/05/2023.03.02.23286561.abstract AB Bivalent COVID-19 vaccines were introduced in 2022 but knowledge of their effectiveness against severe COVID-19 outcomes is currently limited. In Finnish register-based cohort analyses, we compared the risk of severe COVID-19 outcomes among those who received bivalent vaccination (exposed) between September 2022 and March 2023 to those who did not (unexposed). Among elderly aged 65–110 years, bivalent vaccination reduced the risk of hospitalisation and death due to COVID-19 in September–December 2022; the hazard ratios comparing exposed and unexposed ranged from 0.37 to 0.45 during the first 31–60 days since bivalent vaccination. However, in January–March 2023 the effect disappeared possibly indicating immune evasion of new SARS-CoV-2 variants, waning of vaccine effectiveness and increased presence of hybrid immunity. Among the chronically ill aged 18–64 years bivalent vaccination did not reduce the risk of severe COVID-19 outcomes. These results are important for developing COVID-19 vaccines and programmes worldwide.Competing Interest StatementHanna Nohynek is a member of Finnish National Immunization Technical Advisory Groups and chairman of Strategic Advisory Group of Experts on Immunization for World Health Organization.Funding StatementEero Poukka received a grant from The Finnish Medical Foundation. No other sources of external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:By Finnish law, the Finnish Institute for Health and Welfare (THL) is the national expert institution to carry out surveillance on the impact of vaccinations in Finland (Communicable Diseases Act, https://www.finlex.fi/en/laki/kaannokset/2016/en20161227.pdf). Neither specific ethical approval of this study nor informed consent from the participants was needed. The supplements material includes THL Director of the Department for Health Security signatured statement considering the ethical review.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesBy Finnish law, the authors are not permitted to share individual-level register data. The computing code is available upon request.